In tune, studies demonstrated that co-treatment of prostate cancer cells with (decitabine + trichostatin A) was associated with a significant increase in apoptotic activity compared with the single agents alone [14], an effect that seemed to be related to increased ERβ expression. The gene discussed is ESR2; the disease is prostate carcinoma.